If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

6 Sep 2023 07:00

RNS Number : 4715L
Omega Diagnostics Group PLC
06 September 2023
 

Omega Diagnostics Group plc

('Omega' or the 'Company')

 

AGM Statement

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, will hold its Annual General Meeting (AGM) today at 11.00am at Poets House, St Mary's Street, Ely, CB7 4EY.

 

Ahead of the meeting, Simon Douglas, Chairman of the Company, will make the following statement:

 

"At the start of the new financial year we continue to work towards achieving our strategic objectives for our Health and Nutrition Business, maintaining our market leading position whilst targeting organic growth to gain momentum and create value for our shareholders.

 

Whilst we maintain a very strong order book, one of our leading products, the FoodPrint® test, had some production challenges towards the end of the year which resulted in a drop in production yields and, as a consequence, a backlog in the fulfilment of some orders. As announced with our results last month, we have embedded new working practices that are now generating significantly higher production yields that will allow us to successfully address the order backlog. We have established new preventative procedures and will continue to make further improvements. 

 

We remain well-funded to deliver against our strategic objectives. We have started our journey into the US market and we will continue to work closely with strategic partners to develop bespoke microbiome and nutrigenomic test reports. The recent successful launch of our new digital "app", MyHealthTracker, will support our strong position in the market and give us a direct connection with our customers.

 

We are implementing the final parts of the turnaround strategy outlined last year. A turnaround year where we established a clear focus, with new objectives. It has seen a significant shift in the business, and our proposed name change to Cambridge Nutritional Sciences PLC (LON: CNSL) builds on our CNSLab brand and better reflects our goal of promoting a personalised and functional approach to health and nutrition. We will continue to reshape and restructure the Company as we implement our new strategy.

 

Finally, as previously announced, the Board continues to vigorously pursue its substantial counterclaim for losses incurred towards the DHSC, as a direct result of its failure to licence the necessary intellectual property to permit the contract to move forward and their failure to notify the Group of their inability to do so in a timely manner.

 

We as a Board remain positive and believe we are well-positioned to re-focus the business and build an exciting profitable enterprise for everyone and look forward to updating our shareholders in November at the Company's half year results."

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadx.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

Sam Allen

Mob: 07502 558 258

 

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSSEFMIEDSEEU
Date   Source Headline
4th Jan 20224:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSConfirmation of detection of Omicron variant
10th Dec 20212:06 pmRNSSecond Price Monitoring Extn
10th Dec 20212:01 pmRNSPrice Monitoring Extension
10th Dec 20219:30 amRNSDHSC contract update
1st Dec 20214:40 pmRNSSecond Price Monitoring Extn
1st Dec 20214:35 pmRNSPrice Monitoring Extension
1st Dec 20212:05 pmRNSSecond Price Monitoring Extn
1st Dec 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20212:06 pmRNSSecond Price Monitoring Extn
26th Nov 20212:00 pmRNSPrice Monitoring Extension
25th Nov 20219:06 amRNSSecond Price Monitoring Extn
25th Nov 20219:00 amRNSPrice Monitoring Extension
25th Nov 20217:00 amRNSHalf-year Report
5th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 20217:00 amRNSUpdate on CTDA Regulations
1st Nov 20213:28 pmRNSExercise of Options and Total Voting Rights
1st Nov 20217:00 amRNSPartnership with DAM Health and initial LFT order
19th Oct 202112:00 pmRNSExercise of Options and Total Voting Rights
15th Sep 20213:26 pmRNSResult of AGM
15th Sep 20217:00 amRNSAGM Statement
30th Jul 202112:35 pmRNSPosting of Annual Report & Accounts &Notice of AGM
27th Jul 20217:00 amRNSAbC-19 monitors vaccine response to variants
13th Jul 20217:01 amRNSFinal Results
13th Jul 20217:00 amRNSDirectorate Change
9th Jul 20219:08 amRNSAbC-19 rapid antibody test performance evaluation
2nd Jul 20217:00 amRNSFDA submission for Emergency Use Authorization
16th Jun 20217:00 amRNSNotice of Results
15th Jun 202110:49 amRNSStatement re. Media Comment
10th Jun 20212:05 pmRNSSecond Price Monitoring Extn
10th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20217:00 amRNSRegulatory progress for VISITECT® COVID-19 test
7th Jun 20217:00 amRNSProgress update
1st Jun 20217:00 amRNSPositive data for COVID-19 antigen test
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20217:00 amRNSPositive data for Mologic COVID-19 antigen test
30th Apr 20211:30 pmRNSExercise of Options and Total Voting Rights
30th Apr 20217:00 amRNSLaunch of VISITECT® COVID-19 Antigen & Update
23rd Apr 202110:30 amRNSDirector/PDMR Shareholding and Total Voting Rights
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
31st Mar 202112:31 pmRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20215:36 pmRNSExercise of Options and Total Voting Rights
26th Mar 20214:40 pmRNSSecond Price Monitoring Extn
26th Mar 20214:35 pmRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSCE-Mark: Mologic COVID19 lateral flow antigen test
19th Mar 20211:15 pmRNSExercise of Options and Total Voting Rights
15th Mar 20215:28 pmRNSStatement re. Government press release
15th Mar 20217:00 amRNSUK Public Sector Contract disclosure
8th Mar 20217:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.